Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で56.62%の成長率を示しています。
赤字転落
同社の業績は赤字に転じ、最新の年間損失はUSD です。
適正水準
同社の最新のPEは-67.34で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は27.62M株で、前四半期比で6.13%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.28です。